

Declaration of Richard P. Junghans, Ph.D., M.D.

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MILTENYI BIOMEDICINE GmbH and MILTENYI BIOTEC INC.
Petitioner

v.

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Patent Owner

IPR Trial No. IPR2022 -
U.S. Patent No. 9,464,140
Issue Date: October 11, 2016

Title: Compositions and Methods for Treatment of Cancer

DECLARATION OF DR. RICHARD P. JUNGHANS
IN SUPPORT OF PETITION FOR INTER PARTES REVIEW OF
U.S. PATENT NO. 9,464,140

TABLE OF CONTENTS

I.	Introduction.....	1
II.	Education and Experience	2
III.	Materials Considered.....	6
IV.	Technology Background.....	6
	A. T Cells	7
	B. Chimeric Antigen Receptor T Cells (CAR T Cells)	10
	C. Engineering CAR T Cells	14
	D. Immunotherapy with CAR T Cells	18
V.	Person of Ordinary Skill in the Art (“POSA”).....	21
VI.	The ’140 Patent.....	22
VII.	Claim Construction.....	24
	A. Preamble – “treating cancer”	24
	B. “Anti-tumor effective amount”	25
VIII.	Prior Art	28
	A. CAR T-Cell Therapies Known Prior to the Priority Date.....	28
	1. The St. Jude CAR, Known as Anti-CD19-BB-ζ	28
	B. Sequences of the CAR Domains Were Known	34
	1. Anti-CD19 ScFv	34
	2. Human CD8α Leader, Hinge, and Transmembrane Domains	40
	3. 4-1BB Costimulatory Domain	46
	4. CD3-zeta Signaling Domain	46
	C. Animal and Clinical Studies of the Campana CAR.....	48
	1. Milone	48
	2. CART-19 ClinicalTrials.gov.....	51
	3. Porter	54
	D. A Pharmaceutical Composition of CAR T Cells	60
	1. Honsik	61
IX.	Legal Standards	62

Declaration of Richard P. Junghans, Ph.D., M.D.

X.	Ground 1: Independent Claim 1, and Dependent Claims 2, 6, 8-9, 11, 16, 21-22, and 27-28 are rendered obvious by Campana in view of Nicholson, HONSIK, And CART-19 ClinicalTrials.gov.....	65
A.	Independent Claim 1	65
1.	Claim Limitations Directed to the Structure of the Claimed CAR T Cell.....	66
2.	Claim Limitations Directed to a Pharmaceutical Composition Comprising Administering an Anti-tumor Effective Amount of a Population of Human T cells	74
B.	Dependent Claims	93
1.	Claim 2: “anti-tumor effective amount of T cells is 10^4 to 10^9 cells per kg body weight of a human in need of such cells”	93
2.	Claim 6: “wherein the transmembrane domain is CD8 α transmembrane domain”	93
3.	Claims 8 and 9: “wherein the CAR further comprises a hinge domain” or “wherein the hinge domain is a CD8 α hinge domain”	94
4.	Claims 11 and 16: “wherein the 4-1BB costimulatory signaling region comprises the amino acid sequence of SEQ ID NO: 23” and “wherein the 4-1BB costimulatory signaling region comprises the nucleic acid sequence of SEQ ID NO: 17”	94
5.	Claims 21 and 22: “wherein the T cells are T cells of a human having a cancer” or “wherein the cancer is a hematological cancer”	96
6.	Claims 27 and 28: “wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, diluent or excipient” and “wherein the pharmaceutical composition comprises a buffer”	98
XI.	Ground 2: Independent Claim 1, and Dependent Claims 2, 3, 6, 8-9, 11, 13, 16, 21-22, and 27-28 are rendered obvious by Campana in view of Jensen, HONSIK, and CART-19 ClinicalTrials.gov	100
A.	Independent Claim 1	101
1.	Preamble of “[a] method of treating cancer in a human patient”	101

Declaration of Richard P. Junghans, Ph.D., M.D.

2.	“[b] administering to the human patient a pharmaceutical composition”	101
3.	“[c] an anti-tumor effective amount of a population of human T cells”	102
4.	“[d] wherein the T cells comprise a nucleic acid sequence encoding a chimeric antigen receptor (CAR)”	105
5.	“[e] wherein the CAR comprises a CD19 antigen binding domain comprising, from the amino to the carboxy terminus, a light chain variable region and a heavy chain variable region of SEQ ID NO:20”	105
6.	“[f] wherein the CAR further comprises a transmembrane domain, a 4-1BB costimulatory signaling region, and a CD3 zeta signaling domain”	109
B.	Dependent Claim 3: an “anti-tumor effective amount of T cells is 10^5 to 10^6 cells per kg body weight of a human in need of such cells”	109
C.	Claim 13: “wherein the CD19 antigen binding domain is encoded by a nucleic acid sequence comprising SEQ ID NO: 14”	113
D.	Dependent Claims 2, 6, 8-9, 11, 16, 21-22, and 27-28	117
XII.	Ground 3: All Challenged Claims are Rendered Obvious by Campana in View of Milone, CART-19 ClinicalTrials.gov, Sequence Art (Jensen, Nicholson, Littman, Sadelain), AND Honsik.....	118
A.	Independent Claim 1	119
1.	Preamble of “[a] method of treating cancer”	119
2.	“[b] administering to the human patient a pharmaceutical composition”	119
3.	“[c] anti-tumor effective amount of a population of human T cells”	120
4.	“[d] wherein the T cells comprise a nucleic acid sequence encoding a chimeric antigen receptor (CAR)”	126
5.	“[e] wherein the CAR comprises a CD19 antigen binding domain comprising, from the amino to the carboxy terminus, a light chain variable region and a heavy chain variable region of SEQ ID NO:20”	126

Declaration of Richard P. Junghans, Ph.D., M.D.

6.	“[f] wherein the CAR further comprises a transmembrane domain, a 4-1BB costimulatory signaling region, and a “CD3 zeta signaling domain”	127
B.	Sequence Claims	127
1.	The CD8 α Hinge and Transmembrane of the '140 Patent	127
2.	Claims 12 and 17: “wherein the CD3 zeta signaling domain comprises the amino acid sequence of SEQ ID NO: 24” or “wherein the CD3 zeta signaling domain comprises the nucleic acid sequence of SEQ ID NO: 18”	138
3.	Claims 18 and 19: “wherein the CAR comprises amino acid sequence of SEQ ID NO: 12” or “wherein the CAR comprises nucleic acid sequence of SEQ ID NO: 8”	140
4.	Statement About Nucleic and Amino Acid Sequences for CD8 α and CD3-zeta Domains in Campana	142
C.	Vector/Promoter claims.....	147
1.	Claims 23 and 24: “wherein the T cells comprise a vector that comprises the nucleic acid sequence” or “wherein the vector is a lentiviral vector”	147
2.	Claims 25 and 26: “wherein the vector further comprises a promoter” or “wherein the promoter is an EF-1 α promoter”	148
D.	Dependent claims 2-3, 6, 8-9, 11, 13, 16, 21-22, 27- 28.....	150
XIII.	Ground 4: All Challenged Claims are Rendered Obvious by Campana, porter, Sequence Art, AND HONSIK	152
A.	Porter is Prior Art	153
1.	Provisional Applications Do Not Provide Adequate Support for the Claims	153
2.	No Disclosure of SEQ ID NO: 20 in the Provisional Applications	154
3.	Nicholson Teaches a VH-VL Order	157
B.	All Challenged Claims are Rendered Obvious by Campana, Sequence Art, and Porter.....	164
1.	Independent Claim 1	165
C.	Dependent Claims	176

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.